This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options

J. Sloan Manning, MD, and Joseph P. McEvoy, MD

Published: February 21, 2018


Tardive dyskinesia (TD) is a serious condition that affects patients’ ability to control movements. Clinicians who treat patients with either first- (FGA) or second-generation antipsychotics (SGAs) should regularly screen their patients for potential TD symptoms. While SGAs pose less risk than FGAs for developing these symptoms, the risk is not zero. Additionally, other risk factors have been identified to help clinicians identify which patients may have a higher chance of developing these movements. Clinicians have access to numerous screening tools, such as the Abnormal Involuntary Movement Scale (AIMS), that can help identify these difficult-to-detect movements. Footage of an actual patient during a real-time AIMS exam is presented inside this activity. Currently, two medications have been approved by the US Food and Drug Administration for the treatment of TD. During this webcast presentation, listen actively as our faculty discuss both these new treatment options and several older options.

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Do you know which of your patients are at risk for developing tardive dyskinesia? Watch this Webcast to learn about how to prevent tardive dyskinesia in your patients and new treatment strategies for your patients who have already been diagnosed.

J. Sloan Manning, MD
Department of Family Medicine, University of North Carolina, Chapel Hill, and the Mood Disorders Clinic, Cone Family Practice Center, Greensboro, North Carolina
Joseph P. McEvoy, MD
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

CME Background Information

Supported by an educational grant from Neurocrine Continental, Inc., a wholly-owned subsidiary of Neurocrine Biosciences, Inc.

Participants may receive credit by reading the activity, correctly answering the posttest questions, and completing the evaluation.


After completing this educational activity, you should be able to:

  • Routinely use screening tools to identify early signs of tardive dyskinesia in patients who are prescribed medications associated with its risk
  • Employ current evidence-based strategies to manage tardive dyskinesia

Financial Disclosure

The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosures are as follows:

Dr Manning is a consultant for Otsuka, Sunovion, Takeda, Lundbeck, and Alkermes and is a member of the speakers/advisory boards for Otsuka, Sunovion, Takeda, and Lundbeck.

Dr McEvoy is a consultant for Neurocrine and Teva and has received grant/research support from Alkermes, Avanir, Boehringer Ingelheim, and Otsuka.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release, Review, and Expiration Dates

This program was published in November 2017 and is eligible for AMA PRA Category 1 Credits through November 31, 2019. The latest review of this material was October 2017.

Statement of Need and Purpose

Some physicians are unaware that tardive dyskinesia (TD) is associated with second-generation antipsychotic (SGA) agents to a greater extent than previously thought. Education about the prevalence and incidence of TD and risk factors and screening tools is needed because SGAs are used to treat multiple illnesses and the older first-generation antipsychotic agents are also still prescribed. Early recognition is key to management of TD, but subtle signs are easily missed if routine standardized screening is not performed. Survey data show that many psychiatrists have not received training on TD, most do not feel competent in using a screening scale, and most do not discuss TD risk with patients before prescribing antipsychotics. Some clinicians continue treatment unchanged after a movement disorder has appeared because patients are responding so positively to the present treatment regimen. Not only does this increase the chances for TD symptoms to become permanent, it can lead to patient nonadherence, which may ultimately lead to relapse. Therefore, education for physicians is also needed about evidence-based treatment options for patients with TD. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on TD.

Disclosure of Off-Label Usage

Drs Manning and McEvoy have determined that, to the best of their knowledge, valbenazine and deutetrabenazine are the only drugs approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.

Review Process

The entire faculty of the series discussed the content at a peer-review planning session, the Chair reviewed the activity for accuracy and fair balance, and a member of the External CME Advisory Board reviewed the activity to determine whether the material is evidence-based and objective.


This Webcast activity is derived from the planning teleconference series “What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options,” which was held in May and August 2017 and supported by an educational grant from Neurocrine Biosciences, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.


Amantadine hydrochloride[package insert]. Parsippany, NJ: Actavis Pharma, Inc. 2016. Accessed October 17, 2017.

Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595–604.

Animi-3(omega-3 fatty acids)[package insert]. Charlottesville, VA: PBM Pharmaceuticals, Inc. 2013. Accessed October 17, 2017.

Austedo(deutetrabenazine)[package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2017. Accessed October 17,2017.

Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–469. PubMed.

Chlorpromazine hydrochloride[package insert]. Maple Grove, MN: Upsher-Smith Laboratories, Inc. 2017. Accessed October 17, 2017.

Citrome L. Comparing treatments for tardive dyskinesia. Published August 31, 2017. Accessed October 12, 2017.

Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication-what is the number needed to treat, number needed to harm and the likelihood to be helped or harmed? Int J Clin Pract. 2017;71(7). Epub 2017 May 12. PubMed.

Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care. 2007;12(Decision Maker News-Tardive Dyskinesia: Minimizing Risk and Improving Outcomes in Schizophrenia and Other Disorders 1-Decis). Accessed October 12, 2017.

Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–176. PubMed

Clozaril(clozapine)[package insert].East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, 2015. Accessed October 17, 2017.

Correll C. Epidemiology and Prevention of tardive dyskinesia. Published July 31, 2017. Accessed October 12, 2017.

Factor S, Hauser R, Mandri D, et al. A phase 2 study of valbenazine(NBI-98854) for treatment of tardive dyskinesia: KINECT 2 (S27.007). Neurology. 2015;86(16 Suppl): S27.007. Abstract.

Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003–2010. PubMed.

Friedman RA. A call for caution on antipsychotic drugs. Published September 24, 2012. Accessed October 12, 2017.

Gingko biloba[package insert]. Woodbine, IA: Liddell Laboratories, 2010. Accessed October 17, 2017.

Grover S, Hazari N, Kate N, et al. Management of tardive syndromes with clozapine: a case series. Asian J Psychiatr. 2014;8:111–114. PubMed.

Guy W. ECDEU assessment manual for psychopharmacology revised, 1976. Rockville, Maryland:US National Institute of Mental Health;1976:3–603. Link.

Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–484. PubMed.

Inderal LA(propranolol hydrochloride)[package insert]. Cranford, NJ: Akrimax Pharmaceuticals, 2015. Accessed October 17,2017.

Ingrezza(valbenazine)[package insert]. San Diego, CA: Neurocrine Biosciences, 2017. Accessed October 17, 2017.

Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371–1380. PubMed.

Kane JM, Woerner M,Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8(4 Suppl):52S–56S. PubMed.

Kaur N, Kumar, P, Jamwal S, et al. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016;23(3):176–185. PubMed.

Keppra(levetiracetam)[package insert]. Smyrna, GA: UCB Farchim SR, 2010. Accessed October 17,2017.

Klonopin(clonazepam)[package insert]. South San Francisco, CA: Genentech USA, Inc. 2016. Accessed October 17, 2017.

Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56. PubMed.

Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321–334. PubMed.

Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50(11):703–714. PubMed.

Miguel R, Mendonça MD, Barbosa R, et al. Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Ther Adv Neurol Disord. 2017;10(2):81–90. PubMed.

Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33–43. PubMed

O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–1687. PubMed.

Risperdal(risperidone)[package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2017. Accessed October 17,2017.

Seroquel(quetiapine)[package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2017. Accessed October 17,2017.

Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486–487. PubMed

Stagnitti MN. Trends in antipsychotics purchases and expenses for the US civilian noninstitutionalized population, 1997 and 2007. Published July 2010. Accessed October 12, 2017.

Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521–1528. PubMed.

Xenazine(tetrabenazine)[package insert]. Deerfield, IL: Lundbeck, 2017. Accessed October 17, 2017.

Zádori D, Veres G, Szalárdy L, et al. Drug-induced movement disorders. Expert Opin Drug Saf. 2015;14(6):877–890. PubMed.

Zonegran(zonisamide)[package insert]. St. Michael, Barbados, BB11005:Concordia Pharmaceuticals, Inc. 2017. Accessed October 17, 2017.

Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266. PubMed.

Volume: 79

Quick Links: